Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
53°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hims & Hers Health, Inc. Class A Common Stock
(NY:
HIMS
)
54.83
+1.31 (+2.45%)
Official Closing Price
Updated: 7:00 PM EDT, May 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hims & Hers Health, Inc. Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Assessing Hims & Hers Health: Insights From 7 Financial Analysts
February 18, 2025
Via
Benzinga
Hims & Hers Health Stock: A Millionaire-Maker in the Making?
February 18, 2025
The stock has sprinted past $50 per share, after trading at $3 less than two years ago.
Via
The Motley Fool
Hims & Hers Stock: More Gains Ahead Or A Pullback? Most Retail Traders Bet On This Path
February 18, 2025
A poll of over 4,000 respondents found that 47% believe the stock will continue its climb past $60, while 44% expect a significant pullback for profit-taking.
Via
Stocktwits
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
February 17, 2025
Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?
Via
MarketBeat
Super Micro Computer, Intel, Alibaba And CVS Are Among Top 13 Large-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
February 16, 2025
In the last week, these 13 large-cap stocks were top performers. Are they in your portfolio? HIMS, AUR, APP, SMCI, TEM, DKNG, INTC, MNDY, BROS, CVS, BABA, AAPL, ABNB.
Via
Benzinga
Hims & Hers Health Unusual Options Activity For February 10
February 10, 2025
Via
Benzinga
Hims & Hers Health Unusual Options Activity
February 07, 2025
Via
Benzinga
Hims & Hers Health Unusual Options Activity For February 03
February 03, 2025
Via
Benzinga
Stocks Brush Off Global Trade Tensions, PPI Data
February 13, 2025
Stocks are firmly higher today, despite rising global trade tensions and another hotter-than-expected inflation reading.
Via
Talk Markets
Topics
Economy
Stocks / Equities
World Trade
Exposures
Interest Rates
Tariff
Robinhood, Gilead Sciences, Crocs, Lincoln Electric, HubSpot, GE HealthCare And Other Big Stocks Moving Higher On Thursday
February 13, 2025
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 12, 2025
Via
Benzinga
Why Hims & Hers Terrifies Big Pharma
February 12, 2025
Big pharma tried to stop Hims & Hers' Super Bowl ad.
Via
The Motley Fool
Unlocking the Growth Potential of NYSE:HIMS.
January 31, 2025
A fundamental analysis of (NYSE:HIMS): Is HIMS & HERS HEALTH INC (NYSE:HIMS) suited for growth investing?
Via
Chartmill
Is Hims & Hers Health Stock a Buy?
January 28, 2025
Here's a look into one of healthcare's hottest growth stocks.
Via
The Motley Fool
Hims & Hers Health Unusual Options Activity
January 21, 2025
Via
Benzinga
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
February 12, 2025
GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.
Via
MarketBeat
Exposures
Product Safety
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
February 10, 2025
Via
The Motley Fool
Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight
February 10, 2025
The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system.
Via
Stocktwits
US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst
February 10, 2025
U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports.
Via
Benzinga
Topics
World Trade
Exposures
Tariff
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
February 10, 2025
The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads.
Via
Benzinga
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
February 07, 2025
Shares rocketed on Friday, but the company might not be out of hot water yet.
Via
Investor's Business Daily
EXCLUSIVE: Is Super Bowl $7M Ad Cost Worth It? 61% Say No, 18% Say They Looked Up Companies After Last Year's NFL Championship
February 07, 2025
Benzinga readers pick whether a $7 million Super Bowl cost is worth it for companies and how likely they are to look up a company that may be new to them after the big game.
Via
Benzinga
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight
February 07, 2025
A list of Super Bowl LIX commercials and the celebrities and athletes attached to star in the ads.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
February 07, 2025
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also...
Via
Stocktwits
Hims & Hers Launches Health Collective and Community Member Council
February 04, 2025
From
Hims & Hers
Via
Business Wire
Hims & Hers to Announce Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
February 03, 2025
From
Hims & Hers
Via
Business Wire
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
February 02, 2025
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners...
Via
Benzinga
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
January 22, 2025
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions
Via
MarketBeat
8 Health Care Stocks Whale Activity In Today's Session
January 20, 2025
Via
Benzinga
Hims & Hers Health: A Stock to Trade or Own?
January 20, 2025
HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.